NCT02339571 2026-03-19A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaNational Cancer Institute (NCI)Phase 2/3 Active not recruiting600 enrolled
NCT01989572 2020-07-07Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryNational Cancer Institute (NCI)Phase 3 Completed815 enrolled 10 charts